Study on Lixisenatide and Counterregulation to Hypoglycemia

NCT02020629 · Completed

Last updated 2026-05-28

This study tests how the diabetes medication lixisenatide affects the body's response to low blood sugar in adults with type 2 diabetes.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design open-label (no blinding) basic-science study

Participants 18 people

Who can join Ages 18+ · all sexes

Timeline Started 2013-12 · est. completion 2015-08

Where 1 site · Sweden

What this study is testing ClinicalTrials.gov NCT02020629 ↗

Description as written by the study sponsor.

In hypoglycemia, there is a counterregulation to restore glucose levels. An important part of this counterregulation is the release of the hormone glucagon. Since the GLP-1 receptor agonist lixisenatide has been shown to be associated with a low risk of hypoglycemia, this study examines whether lixisenatide affects the glucagon response to hypoglycemia.

Treatments tested

Lixisenatide also known as Lyxumia Drug

Lixisenatide is given for 6 weeks whereafter a hypoglycemia clamp is undertaken

Main thing measured	Glucagon response to hypoglycemia
Sponsor	Lund University
Conditions studied	Type 2 Diabetes
GLP-1 drugs	lixisenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02020629 ↗